Vaccine

TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+…

3 years ago

TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program

FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company…

3 years ago

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

-Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-SAN DIEGO, Calif., April 27, 2023 (GLOBE…

3 years ago

Press Release: Sanofi completes acquisition of Provention Bio, Inc.

Sanofi completes acquisition of Provention Bio, Inc. Paris, April 27 2023. Sanofi announced today the completion of its acquisition of…

3 years ago

MI4, Montreal’s powerhouse of infectious disease research, celebrates five years of innovation and philanthropy

Vincent Chiara, real estate entrepreneur and founder and President of Groupe Mach donates $1.4 million to the MUCH Foundation for…

3 years ago

Teknova to Report First Quarter 2023 Financial Results on May 10, 2023

HOLLISTER, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents…

3 years ago

TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio

Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.”BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- TransCode…

3 years ago

Decentralized Trials & Research Alliance Shares Patient Journey Maps Across Three Therapeutic Areas

Global Cross-Industry Collaboration Continues Sharing Outputs to Improve Research Access SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- The Decentralized…

3 years ago

Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab

Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER,…

3 years ago